Document Detail


Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature.
MedLine Citation:
PMID:  22170228     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Acquired factor VIII inhibitor (AFI) is a rare disorder and is even more uncommon in multiple myeloma patients, with only five cases reported in literature. Solid and hematologic malignancies, autoimmune conditions, drugs, and infections are the conditions commonly associated with the development of this condition, with mucocutaneous bleeding being the most common presenting sign. Diagnosis is usually made with the laboratory finding of an elevated partial thromboplastin time aPTT that cannot be corrected by plasma mixing, and further confirmed by low factor VIII activity/antigen levels along with elevated factor VIII inhibitor levels using the Bethesda assay. Treatment is usually based on the clinical picture with factor VIII inhibitor bypass activity (FEIBA) and recombinant factor VIIa (rFVIIa) employed to control acute bleeding; steroids and cyclophosphamide to suppress the inhibitor with Rituximab, in combination with other immunosuppressants in cases not suitable for steroids, and finally wherever possible, to remove the offending drug or control the underlying pathology that might predispose to the development of this condition. This case report highlights the successful management of a myeloma patient who presented with life-threatening hemorrhagic pericardial effusion and hemarthrosis. The patient was treated with FEIBA to control the acute bleeding and then received Rituximab in combination with intravenous immunoglobulin to suppress the AFI.
Authors:
Jameel Muzaffar; Lakshmikanth Katragadda; Sajjad Haider; Ali Javed; Elias Anaissie; Saad Usmani
Related Documents :
9437328 - Bilateral multifocal retinal arteriolar sheathing as the only ocular finding in heredit...
22183578 - An analysis of quality of systematic reviews on pharmacist health interventions.
21859408 - A systematic literature review: self-mutilation among adolescents as a phenomenon and h...
22056768 - Epidemiology of snakebites in europe: a systematic review of the literature.
24885018 - Improving rheumatic fever surveillance in new zealand: results of a surveillance sector...
6544858 - The pale epiglottitis--a misnomer or not?
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-12-15
Journal Detail:
Title:  International journal of hematology     Volume:  -     ISSN:  1865-3774     ISO Abbreviation:  -     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West. Markham Street, Little Rock, AR, 72205, USA, jameel_muzaffar@yahoo.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Childhood acute bacterial meningitis: risk factors for acute neurological complications and neurolog...
Next Document:  Epstein-Barr virus-associated post-transplant lymphoproliferative disorders after allogeneic periphe...